WO2001025248A2 - Design of high affinity rnase h recruiting oligonucleotide - Google Patents
Design of high affinity rnase h recruiting oligonucleotide Download PDFInfo
- Publication number
- WO2001025248A2 WO2001025248A2 PCT/DK2000/000550 DK0000550W WO0125248A2 WO 2001025248 A2 WO2001025248 A2 WO 2001025248A2 DK 0000550 W DK0000550 W DK 0000550W WO 0125248 A2 WO0125248 A2 WO 0125248A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lna
- oxy
- oligo
- high affinity
- monomers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002385853A CA2385853A1 (en) | 1999-10-04 | 2000-10-03 | Design of high affinity rnase h recruiting oligonucleotide |
EP00962273A EP1224280A2 (en) | 1999-10-04 | 2000-10-03 | Design of high affinity rnase h recruiting oligonucleotide |
IL14891600A IL148916A0 (en) | 1999-10-04 | 2000-10-03 | Design of high affinity rnase h recruiting oligonucleotide |
AU74067/00A AU7406700A (en) | 1999-10-04 | 2000-10-03 | Design of high affinity rnase h recruiting oligonucleotide |
JP2001528192A JP2003511016A (en) | 1999-10-04 | 2000-10-03 | Design of High Affinity RNase H to Replenish Oligonucleotides |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA199901422 | 1999-10-04 | ||
DKPA199901422 | 1999-10-04 | ||
US15772499P | 1999-10-05 | 1999-10-05 | |
US60/157,724 | 1999-10-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001025248A2 true WO2001025248A2 (en) | 2001-04-12 |
WO2001025248A3 WO2001025248A3 (en) | 2001-08-30 |
Family
ID=26065735
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK2000/000550 WO2001025248A2 (en) | 1999-10-04 | 2000-10-03 | Design of high affinity rnase h recruiting oligonucleotide |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1224280A2 (en) |
JP (1) | JP2003511016A (en) |
AU (1) | AU7406700A (en) |
CA (1) | CA2385853A1 (en) |
IL (1) | IL148916A0 (en) |
WO (1) | WO2001025248A2 (en) |
Cited By (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003039523A2 (en) * | 2001-11-05 | 2003-05-15 | Exiqon A/S | OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES |
WO2004046160A2 (en) * | 2002-11-18 | 2004-06-03 | Santaris Pharma A/S | Amino-lna, thio-lna and alpha-l-oxy-ln |
WO2005061710A1 (en) | 2003-12-23 | 2005-07-07 | Santaris Pharma A/S | Oligomeric compounds for the modulation of bcl-2 |
WO2006050734A2 (en) | 2004-11-09 | 2006-05-18 | Santaris Pharma A/S | Potent lna oligonucleotides for the inhibition of hif-1a expression |
WO2007027894A3 (en) * | 2005-08-29 | 2007-05-31 | Isis Pharmaceuticals Inc | Antisense compounds having enhanced anti-microrna activity |
WO2008153933A2 (en) | 2007-06-06 | 2008-12-18 | Avi Biopharma, Inc. | Soluble her2 and her3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease |
WO2009043353A2 (en) | 2007-10-04 | 2009-04-09 | Santaris Pharma A/S | Micromirs |
US7713738B2 (en) | 2003-02-10 | 2010-05-11 | Enzon Pharmaceuticals, Inc. | Oligomeric compounds for the modulation of survivin expression |
EP2194129A2 (en) | 2006-04-03 | 2010-06-09 | Santaris Pharma A/S | Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides |
US7737264B2 (en) | 2002-04-05 | 2010-06-15 | Enzon Pharmaceuticals, Inc. | Oligomeric compounds for the modulation HIF-1α expression |
EP2261333A2 (en) | 2006-04-03 | 2010-12-15 | Santaris Pharma A/S | Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides |
WO2011105901A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 9 (c9) and uses thereof |
WO2011105902A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 8-beta (c8-beta) and uses thereof |
WO2011105900A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 8-alpha (c8-alpha) and uses thereof |
WO2012010711A1 (en) | 2010-07-23 | 2012-01-26 | Santaris Pharma A/S | Process |
WO2012027206A1 (en) | 2010-08-24 | 2012-03-01 | Merck Sharp & Dohme Corp. | SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER |
US8129515B2 (en) * | 2006-01-27 | 2012-03-06 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of microRNAs |
US8173428B2 (en) | 2004-11-09 | 2012-05-08 | Santaris Pharma A/S | LNA oligonucleotides and the treatment of cancer |
US8299237B2 (en) | 2007-08-30 | 2012-10-30 | Hadasit Medical Research Services & Development Ltd. | Nucleic acid sequences comprising NF-κB binding site within O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter region and uses thereof for the treatment of cancer and immune-related disorders |
US8329888B2 (en) | 2006-03-23 | 2012-12-11 | Santaris Pharma A/S | Small internally segmented interfering RNA |
US8361980B2 (en) | 2008-03-07 | 2013-01-29 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microRNA related diseases |
US8470791B2 (en) | 2007-03-22 | 2013-06-25 | Santaris Pharma A/S | RNA antagonist compounds for the inhibition of Apo-B100 expression |
US8492357B2 (en) | 2008-08-01 | 2013-07-23 | Santaris Pharma A/S | Micro-RNA mediated modulation of colony stimulating factors |
US8546350B2 (en) | 2003-07-31 | 2013-10-01 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
US8563528B2 (en) | 2009-07-21 | 2013-10-22 | Santaris Pharma A/S | Antisense oligomers targeting PCSK9 |
US8580756B2 (en) | 2007-03-22 | 2013-11-12 | Santaris Pharma A/S | Short oligomer antagonist compounds for the modulation of target mRNA |
US8653252B2 (en) | 2003-03-21 | 2014-02-18 | Santaris Pharma A/S | Short interfering RNA (siRNA) analogues |
WO2014043544A1 (en) | 2012-09-14 | 2014-03-20 | Rana Therapeutics, Inc. | Multimeric oligonucleotide compounds |
WO2014071406A1 (en) | 2012-11-05 | 2014-05-08 | Pronai Therapeutics, Inc. | Methods of using biomarkers for the treatment of cancer by modulation of bcl2|expression |
WO2014108759A1 (en) | 2013-01-14 | 2014-07-17 | Pierfrancesco Tassone | INHIBITORS OF miRNAs 221 AND 222 FOR ANTI-TUMOR ACTIVITY IN MULTIPLE MYELOMA |
WO2014118267A1 (en) * | 2013-01-30 | 2014-08-07 | Santaris Pharma A/S | Lna oligonucleotide carbohydrate conjugates |
US8969314B2 (en) | 2003-07-31 | 2015-03-03 | Regulus Therapeutics, Inc. | Methods for use in modulating miR-122a |
AU2013201763B2 (en) * | 2002-11-18 | 2015-05-07 | Roche Innovation Center Copenhagen A/S | Amino-LNA, thio-LNA and alpha-L-oxy-LN |
US9034837B2 (en) | 2009-04-24 | 2015-05-19 | Roche Innovation Center Copenhagen A/S | Pharmaceutical compositions for treatment of HCV patients that are poor-responders to interferon |
WO2015075166A1 (en) | 2013-11-22 | 2015-05-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treatment of a bacterial infection |
WO2015118407A2 (en) | 2014-01-29 | 2015-08-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Oligonucleotides and methods for inhibiting or reducing bacterial biofilms |
US9157083B2 (en) | 2013-05-01 | 2015-10-13 | Regulus Therapeutics Inc. | MicroRNA compounds and methods for modulating miR-122 |
US9211537B2 (en) | 2007-11-07 | 2015-12-15 | The University Of British Columbia | Microfluidic device and method of using same |
WO2016041058A1 (en) | 2014-09-18 | 2016-03-24 | The University Of British Columbia | Allele-specific therapy for huntington disease haplotypes |
EP3000480A1 (en) | 2005-12-01 | 2016-03-30 | ProNAi Therapeutics, Inc. | Cancer therapies and pharmaceutical compositions used therein |
US9447138B2 (en) | 2004-11-09 | 2016-09-20 | Roche Innovation Center Copenhagen A/S | Potent LNA oligonucleotides for the inhibition of HIF-1a expression |
US9464106B2 (en) | 2002-10-21 | 2016-10-11 | Exiqon A/S | Oligonucleotides useful for detecting and analyzing nucleic acids of interest |
US9506030B2 (en) | 2013-05-01 | 2016-11-29 | Regulus Therapeutics Inc. | Compounds and methods for enhanced cellular uptake |
AU2015204315B2 (en) * | 2002-11-18 | 2017-06-22 | Roche Innovation Center Copenhagen A/S | Amino-LNA, thio-LNA and alpha-L-oxy-LN |
US9879265B2 (en) | 2013-06-27 | 2018-01-30 | Roche Innovation Center Copenhagen A/S | Oligonucleotide conjugates |
WO2018024849A1 (en) | 2016-08-03 | 2018-02-08 | Aalborg Universitet | ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS |
US10077443B2 (en) | 2012-11-15 | 2018-09-18 | Roche Innovation Center Copenhagen A/S | Oligonucleotide conjugates |
WO2019076919A1 (en) | 2017-10-17 | 2019-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combination treatment for cystic fibrosis |
EP3533873A1 (en) | 2011-09-14 | 2019-09-04 | Translate Bio MA, Inc. | Multimeric oligonucleotide compounds |
WO2021005223A1 (en) | 2019-07-10 | 2021-01-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of epilepsy |
IT201900017234A1 (en) | 2019-09-25 | 2021-03-25 | Int Centre For Genetic Engineering And Biotechnology | Anti-miRNA for the treatment of leiomyoma |
WO2021074657A1 (en) | 2019-10-17 | 2021-04-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combination treatment for cystic fibrosis |
WO2021099394A1 (en) | 2019-11-19 | 2021-05-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antisense oligonucleotides and their use for the treatment of cancer |
WO2022011262A1 (en) | 2020-07-10 | 2022-01-13 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating epilepsy |
WO2022174113A1 (en) | 2021-02-12 | 2022-08-18 | Merand Pharmaceuticals, Inc. | Agents, compositions, and methods for the treatment of hypoxia and ischemia-related disorders |
WO2022200633A1 (en) | 2021-03-26 | 2022-09-29 | Neumirna Therapeutics Aps | Microrna-27b inhibitors |
WO2022200632A1 (en) | 2021-03-26 | 2022-09-29 | Neumirna Therapeutics Aps | Microrna-134 inhibitors |
WO2022254021A1 (en) | 2021-06-04 | 2022-12-08 | Neumirna Therapeutics Aps | Antisense oligonucleotides targeting adenosine kinase |
WO2023022504A1 (en) | 2021-08-17 | 2023-02-23 | 한국과학기술원 | Antisense oligonucleotide targeting cav3.1 gene and uses thereof |
WO2023021184A1 (en) | 2021-08-19 | 2023-02-23 | Neumirna Therapeutics Aps | Antisense oligonucleotides targeting adenosine kinase |
WO2023152369A1 (en) | 2022-02-14 | 2023-08-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Nucleic acid mir-9 inhibitor for the treatment of cystic fibrosis |
WO2024017990A1 (en) | 2022-07-21 | 2024-01-25 | Institut National de la Santé et de la Recherche Médicale | Methods and compositions for treating chronic pain disorders |
EP4332239A1 (en) | 2022-08-30 | 2024-03-06 | Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. | Mir-based assay for gastro-entero-pancreatic neuroendocrine tumor diagnosis and prognosis |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995014706A1 (en) * | 1993-11-24 | 1995-06-01 | Isis Pharmaceuticals, Inc. | Pna-dna-pna chimeric macromolecules |
WO1999014226A2 (en) * | 1997-09-12 | 1999-03-25 | Exiqon A/S | Bi- and tri-cyclic nucleoside, nucleotide and oligonucleotide analogues |
-
2000
- 2000-10-03 JP JP2001528192A patent/JP2003511016A/en active Pending
- 2000-10-03 CA CA002385853A patent/CA2385853A1/en not_active Abandoned
- 2000-10-03 WO PCT/DK2000/000550 patent/WO2001025248A2/en not_active Application Discontinuation
- 2000-10-03 IL IL14891600A patent/IL148916A0/en unknown
- 2000-10-03 AU AU74067/00A patent/AU7406700A/en not_active Abandoned
- 2000-10-03 EP EP00962273A patent/EP1224280A2/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995014706A1 (en) * | 1993-11-24 | 1995-06-01 | Isis Pharmaceuticals, Inc. | Pna-dna-pna chimeric macromolecules |
WO1999014226A2 (en) * | 1997-09-12 | 1999-03-25 | Exiqon A/S | Bi- and tri-cyclic nucleoside, nucleotide and oligonucleotide analogues |
Non-Patent Citations (2)
Title |
---|
KOSHKIN A A ET AL: "LNA (Locked Nucleic Acid): An RNA mimic forming exceedingly stable LNA:LNA duplexes" J.AM. CHEM. SOC., vol. 120, 1998, pages 13252-13253, XP002901504 * |
WAHLESTEDT C ET AL: "Potent and nontoxic antisense oligonucleotides containing locked nucleic acids" PNAS, vol. 97, no. 10, 9 May 2000 (2000-05-09), pages 5633-5638, XP002901503 * |
Cited By (136)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003039523A3 (en) * | 2001-11-05 | 2003-12-04 | Exiqon As | OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES |
WO2003039523A2 (en) * | 2001-11-05 | 2003-05-15 | Exiqon A/S | OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES |
US7737264B2 (en) | 2002-04-05 | 2010-06-15 | Enzon Pharmaceuticals, Inc. | Oligomeric compounds for the modulation HIF-1α expression |
US8785617B2 (en) | 2002-04-05 | 2014-07-22 | Santaris Pharma A/S | Oligomeric compounds for the modulation of HIF-1A expression |
US8357670B2 (en) | 2002-04-05 | 2013-01-22 | Enzon Pharmaceuticals, Inc. | Oligomeric compounds for the modulation of HIF-1A expression |
US8207140B2 (en) | 2002-04-05 | 2012-06-26 | Santaris Pharma A/S | Oligomeric compounds for the modulation of HIF-1α expression |
US7846911B2 (en) | 2002-04-05 | 2010-12-07 | Enzon Pharmaceuticals, Inc. | Oligomeric compounds for the modulation of HIF-1alpha expression |
US9464106B2 (en) | 2002-10-21 | 2016-10-11 | Exiqon A/S | Oligonucleotides useful for detecting and analyzing nucleic acids of interest |
AU2003281969B2 (en) * | 2002-11-18 | 2011-01-27 | Roche Innovation Center Copenhagen A/S | Amino-LNA, thio-LNA and alpha-L-oxy-LN |
US9708614B2 (en) | 2002-11-18 | 2017-07-18 | Roche Innovation Center Copenhagen A/S | Antisense design |
US9428534B2 (en) | 2002-11-18 | 2016-08-30 | Roche Innovation Center Copenhagen A/S | Antisense design |
EP2141233A1 (en) * | 2002-11-18 | 2010-01-06 | Santaris Pharma A/S | Antisense design |
US7687617B2 (en) | 2002-11-18 | 2010-03-30 | Santaris Pharma A/S | Oligonucleotides with alternating segments of locked and non-locked nucleotides |
US9994850B2 (en) | 2002-11-18 | 2018-06-12 | Roche Innovation Center Copenhagen A/S | Antisense design |
US9045518B2 (en) | 2002-11-18 | 2015-06-02 | Santaris Pharma A/S | Amino-LNA, thio-LNA and alpha-L-oxy-LN |
WO2004046160A2 (en) * | 2002-11-18 | 2004-06-03 | Santaris Pharma A/S | Amino-lna, thio-lna and alpha-l-oxy-ln |
US9951333B2 (en) | 2002-11-18 | 2018-04-24 | Roche Innovation Center Copenhagen A/S | Antisense design |
AU2013201763B2 (en) * | 2002-11-18 | 2015-05-07 | Roche Innovation Center Copenhagen A/S | Amino-LNA, thio-LNA and alpha-L-oxy-LN |
EP2752488A3 (en) * | 2002-11-18 | 2014-10-08 | Santaris Pharma A/S | Antisense design |
US9890383B2 (en) | 2002-11-18 | 2018-02-13 | Roche Innovation Center Copenhagen A/S | Antisense design |
US20140296502A1 (en) * | 2002-11-18 | 2014-10-02 | Santaris Pharma A/S | Antisense design |
WO2004046160A3 (en) * | 2002-11-18 | 2004-10-21 | Santaris Pharma As | Amino-lna, thio-lna and alpha-l-oxy-ln |
AU2017232083B2 (en) * | 2002-11-18 | 2019-07-25 | Roche Innovation Center Copenhagen A/S | Amino-LNA, thio-LNA and alpha-L-oxy-LN |
AU2015204315B2 (en) * | 2002-11-18 | 2017-06-22 | Roche Innovation Center Copenhagen A/S | Amino-LNA, thio-LNA and alpha-L-oxy-LN |
EP2284269A3 (en) * | 2002-11-18 | 2012-08-01 | Santaris Pharma A/S | Antisense design |
EP3222722A1 (en) * | 2002-11-18 | 2017-09-27 | Roche Innovation Center Copenhagen A/S | Antisense design |
US8026355B2 (en) | 2003-02-10 | 2011-09-27 | Santaris Pharma A/S | Oligomeric compounds for the modulation of survivin expression |
US7741309B2 (en) | 2003-02-10 | 2010-06-22 | Enzon Pharmaceuticals | Oligomeric compounds for the modulation of survivin expression |
US7713738B2 (en) | 2003-02-10 | 2010-05-11 | Enzon Pharmaceuticals, Inc. | Oligomeric compounds for the modulation of survivin expression |
US8653252B2 (en) | 2003-03-21 | 2014-02-18 | Santaris Pharma A/S | Short interfering RNA (siRNA) analogues |
US9738894B2 (en) | 2003-03-21 | 2017-08-22 | Roche Innovation Center Copenhagen A/S | Short interfering RNA (siRNA) analogues |
US9297010B2 (en) | 2003-03-21 | 2016-03-29 | Roche Innovation Center Copenhagen A/S | Short interfering RNA (siRNA) analogues |
US9663787B2 (en) | 2003-07-31 | 2017-05-30 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
US8969314B2 (en) | 2003-07-31 | 2015-03-03 | Regulus Therapeutics, Inc. | Methods for use in modulating miR-122a |
US9267138B2 (en) | 2003-07-31 | 2016-02-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
US9447412B2 (en) | 2003-07-31 | 2016-09-20 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAS |
US9139832B2 (en) | 2003-07-31 | 2015-09-22 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
US9447413B2 (en) | 2003-07-31 | 2016-09-20 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
US9994842B2 (en) | 2003-07-31 | 2018-06-12 | Regulus Therapeutics Inc. | Methods for use in modulating miR-122A |
US8946179B2 (en) | 2003-07-31 | 2015-02-03 | Regulus Therapeutics, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
US10584336B2 (en) | 2003-07-31 | 2020-03-10 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
US9528108B2 (en) | 2003-07-31 | 2016-12-27 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAS |
US8859521B2 (en) | 2003-07-31 | 2014-10-14 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
US8809294B2 (en) | 2003-07-31 | 2014-08-19 | Regulus Therapeutics Inc. | Method of inhibiting miR-33 using a modified oligonucleotide |
US10072265B2 (en) | 2003-07-31 | 2018-09-11 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
US8546350B2 (en) | 2003-07-31 | 2013-10-01 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
US9752146B2 (en) | 2003-07-31 | 2017-09-05 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
US8765701B2 (en) | 2003-07-31 | 2014-07-01 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
US10093926B2 (en) | 2003-07-31 | 2018-10-09 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
US8697663B2 (en) | 2003-07-31 | 2014-04-15 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
WO2005061710A1 (en) | 2003-12-23 | 2005-07-07 | Santaris Pharma A/S | Oligomeric compounds for the modulation of bcl-2 |
US7622453B2 (en) | 2003-12-23 | 2009-11-24 | Santaris Pharma A/S | Oligomeric compounds for the modulation of Bcl-2 |
US8173428B2 (en) | 2004-11-09 | 2012-05-08 | Santaris Pharma A/S | LNA oligonucleotides and the treatment of cancer |
US7939507B2 (en) | 2004-11-09 | 2011-05-10 | Enzon Pharmaceuticals, Inc. | Potent LNA oligonucleotides for the inhibition of HIF-1a expression |
US9938527B2 (en) | 2004-11-09 | 2018-04-10 | Roche Innovation Center Copenhagen A/S | Potent LNA oligonucleotides for the inhibition of HIF-1A expression |
US7589190B2 (en) | 2004-11-09 | 2009-09-15 | Enzon Pharmaceuticals, Inc. | Potent LNA oligonucleotides for the inhibition of HIF-1A expression |
WO2006050734A2 (en) | 2004-11-09 | 2006-05-18 | Santaris Pharma A/S | Potent lna oligonucleotides for the inhibition of hif-1a expression |
US9447138B2 (en) | 2004-11-09 | 2016-09-20 | Roche Innovation Center Copenhagen A/S | Potent LNA oligonucleotides for the inhibition of HIF-1a expression |
US8410071B2 (en) | 2004-11-09 | 2013-04-02 | Santaris Pharma A/S | Potent LNA oligonucleotides for the inhibition of HIF-1A expression |
WO2007027894A3 (en) * | 2005-08-29 | 2007-05-31 | Isis Pharmaceuticals Inc | Antisense compounds having enhanced anti-microrna activity |
EP3000480A1 (en) | 2005-12-01 | 2016-03-30 | ProNAi Therapeutics, Inc. | Cancer therapies and pharmaceutical compositions used therein |
US20120115228A1 (en) * | 2006-01-27 | 2012-05-10 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of micrornas |
US9127272B2 (en) * | 2006-01-27 | 2015-09-08 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of target nucleic acids |
US8129515B2 (en) * | 2006-01-27 | 2012-03-06 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of microRNAs |
US8329888B2 (en) | 2006-03-23 | 2012-12-11 | Santaris Pharma A/S | Small internally segmented interfering RNA |
EP2261333A2 (en) | 2006-04-03 | 2010-12-15 | Santaris Pharma A/S | Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides |
US8729250B2 (en) | 2006-04-03 | 2014-05-20 | Joacim Elmén | Antisense oligonucleotides for inhibition of microRNA-21 |
EP2194129A2 (en) | 2006-04-03 | 2010-06-09 | Santaris Pharma A/S | Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides |
EP3502255A1 (en) | 2006-04-03 | 2019-06-26 | Roche Innovation Center Copenhagen A/S | Pharmaceutical composition |
US8163708B2 (en) | 2006-04-03 | 2012-04-24 | Santaris Pharma A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotide |
EP3431602A1 (en) | 2006-04-03 | 2019-01-23 | Roche Innovation Center Copenhagen A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
US8580756B2 (en) | 2007-03-22 | 2013-11-12 | Santaris Pharma A/S | Short oligomer antagonist compounds for the modulation of target mRNA |
US8470791B2 (en) | 2007-03-22 | 2013-06-25 | Santaris Pharma A/S | RNA antagonist compounds for the inhibition of Apo-B100 expression |
WO2008153933A2 (en) | 2007-06-06 | 2008-12-18 | Avi Biopharma, Inc. | Soluble her2 and her3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease |
US7884194B2 (en) | 2007-06-06 | 2011-02-08 | Avi Biopharma Inc. | Soluble HER2 and HER3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease |
US8299237B2 (en) | 2007-08-30 | 2012-10-30 | Hadasit Medical Research Services & Development Ltd. | Nucleic acid sequences comprising NF-κB binding site within O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter region and uses thereof for the treatment of cancer and immune-related disorders |
US8906871B2 (en) | 2007-10-04 | 2014-12-09 | Santaris Pharma A/S | MicromiRs |
EP3492594A1 (en) | 2007-10-04 | 2019-06-05 | Roche Innovation Center Copenhagen A/S | Micromirs |
WO2009043353A2 (en) | 2007-10-04 | 2009-04-09 | Santaris Pharma A/S | Micromirs |
US8288356B2 (en) | 2007-10-04 | 2012-10-16 | Santaris Pharma A/S | MicroRNAs |
US10450564B2 (en) | 2007-10-04 | 2019-10-22 | Roche Innovation Center Copenhagen A/S | Micromirs |
EP2623598A1 (en) | 2007-10-04 | 2013-08-07 | Santaris Pharma A/S | Micromirs |
US8440637B2 (en) | 2007-10-04 | 2013-05-14 | Santaris Pharma A/S | Combination treatment for the treatment of hepatitis C virus infection |
US9211537B2 (en) | 2007-11-07 | 2015-12-15 | The University Of British Columbia | Microfluidic device and method of using same |
US8404659B2 (en) | 2008-03-07 | 2013-03-26 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of MicroRNA related diseases |
US8361980B2 (en) | 2008-03-07 | 2013-01-29 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microRNA related diseases |
US8492357B2 (en) | 2008-08-01 | 2013-07-23 | Santaris Pharma A/S | Micro-RNA mediated modulation of colony stimulating factors |
US9034837B2 (en) | 2009-04-24 | 2015-05-19 | Roche Innovation Center Copenhagen A/S | Pharmaceutical compositions for treatment of HCV patients that are poor-responders to interferon |
US8563528B2 (en) | 2009-07-21 | 2013-10-22 | Santaris Pharma A/S | Antisense oligomers targeting PCSK9 |
WO2011105901A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 9 (c9) and uses thereof |
WO2011105902A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 8-beta (c8-beta) and uses thereof |
WO2011105900A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 8-alpha (c8-alpha) and uses thereof |
WO2012010711A1 (en) | 2010-07-23 | 2012-01-26 | Santaris Pharma A/S | Process |
WO2012027206A1 (en) | 2010-08-24 | 2012-03-01 | Merck Sharp & Dohme Corp. | SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER |
EP3533873A1 (en) | 2011-09-14 | 2019-09-04 | Translate Bio MA, Inc. | Multimeric oligonucleotide compounds |
WO2014043544A1 (en) | 2012-09-14 | 2014-03-20 | Rana Therapeutics, Inc. | Multimeric oligonucleotide compounds |
WO2014071406A1 (en) | 2012-11-05 | 2014-05-08 | Pronai Therapeutics, Inc. | Methods of using biomarkers for the treatment of cancer by modulation of bcl2|expression |
US11155816B2 (en) | 2012-11-15 | 2021-10-26 | Roche Innovation Center Copenhagen A/S | Oligonucleotide conjugates |
US10077443B2 (en) | 2012-11-15 | 2018-09-18 | Roche Innovation Center Copenhagen A/S | Oligonucleotide conjugates |
WO2014108759A1 (en) | 2013-01-14 | 2014-07-17 | Pierfrancesco Tassone | INHIBITORS OF miRNAs 221 AND 222 FOR ANTI-TUMOR ACTIVITY IN MULTIPLE MYELOMA |
WO2014118267A1 (en) * | 2013-01-30 | 2014-08-07 | Santaris Pharma A/S | Lna oligonucleotide carbohydrate conjugates |
CN104955952A (en) * | 2013-01-30 | 2015-09-30 | 弗·哈夫曼-拉罗切有限公司 | Lna oligonucleotide carbohydrate conjugates |
US10240151B2 (en) | 2013-05-01 | 2019-03-26 | Regulus Therapeutics Inc. | Compounds and methods for enhanced cellular uptake |
US9506030B2 (en) | 2013-05-01 | 2016-11-29 | Regulus Therapeutics Inc. | Compounds and methods for enhanced cellular uptake |
US10150967B2 (en) | 2013-05-01 | 2018-12-11 | Regulus Therapeutics Inc. | MicroRNA compounds and methods for modulating miR-122 |
US10941400B2 (en) | 2013-05-01 | 2021-03-09 | Regulus Therapeutics Inc. | Compounds and methods for enhanced cellular uptake |
US9157083B2 (en) | 2013-05-01 | 2015-10-13 | Regulus Therapeutics Inc. | MicroRNA compounds and methods for modulating miR-122 |
US9309513B2 (en) | 2013-05-01 | 2016-04-12 | Regulus Therapeutics Inc. | MicroRNA compounds and methods for modulating miR-122 |
US9574194B2 (en) | 2013-05-01 | 2017-02-21 | Regulus Therapeutics Inc. | MicroRNA compounds and methods for modulating miR-122 |
US9879265B2 (en) | 2013-06-27 | 2018-01-30 | Roche Innovation Center Copenhagen A/S | Oligonucleotide conjugates |
US10370668B2 (en) | 2013-06-27 | 2019-08-06 | Roche Innovation Center Copenhagen A/S | Manufacture of antisense oligomers and conjugates targeting PCSK9 |
US10385342B2 (en) | 2013-06-27 | 2019-08-20 | Roche Innovation Center Copenhagen A/S | Methods of treatment using antisense oligomers and conjugates targeting PCSK9 |
US10443058B2 (en) | 2013-06-27 | 2019-10-15 | Roche Innovation Center Copenhagen A/S | Antisense oligomers targeting PCSK9 |
US11739332B2 (en) | 2013-06-27 | 2023-08-29 | Roche Innovation Center Copenhagen A/S | Antisense oligomers targeting PCSK9 |
WO2015075166A1 (en) | 2013-11-22 | 2015-05-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treatment of a bacterial infection |
WO2015118407A2 (en) | 2014-01-29 | 2015-08-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Oligonucleotides and methods for inhibiting or reducing bacterial biofilms |
WO2016041058A1 (en) | 2014-09-18 | 2016-03-24 | The University Of British Columbia | Allele-specific therapy for huntington disease haplotypes |
WO2018024849A1 (en) | 2016-08-03 | 2018-02-08 | Aalborg Universitet | ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS |
WO2019076919A1 (en) | 2017-10-17 | 2019-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combination treatment for cystic fibrosis |
WO2021005223A1 (en) | 2019-07-10 | 2021-01-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of epilepsy |
WO2022008725A1 (en) | 2019-07-10 | 2022-01-13 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Compounds for use in the treatment of epilepsy |
WO2021058524A1 (en) | 2019-09-25 | 2021-04-01 | International Centre For Genetic Engineering And Biotechnology - Icgeb | Anti-mirnas for the treatment of leiomyoma |
IT201900017234A1 (en) | 2019-09-25 | 2021-03-25 | Int Centre For Genetic Engineering And Biotechnology | Anti-miRNA for the treatment of leiomyoma |
WO2021074657A1 (en) | 2019-10-17 | 2021-04-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combination treatment for cystic fibrosis |
WO2021099394A1 (en) | 2019-11-19 | 2021-05-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antisense oligonucleotides and their use for the treatment of cancer |
WO2022011262A1 (en) | 2020-07-10 | 2022-01-13 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating epilepsy |
WO2022174113A1 (en) | 2021-02-12 | 2022-08-18 | Merand Pharmaceuticals, Inc. | Agents, compositions, and methods for the treatment of hypoxia and ischemia-related disorders |
WO2022200633A1 (en) | 2021-03-26 | 2022-09-29 | Neumirna Therapeutics Aps | Microrna-27b inhibitors |
WO2022200632A1 (en) | 2021-03-26 | 2022-09-29 | Neumirna Therapeutics Aps | Microrna-134 inhibitors |
WO2022254021A1 (en) | 2021-06-04 | 2022-12-08 | Neumirna Therapeutics Aps | Antisense oligonucleotides targeting adenosine kinase |
WO2023022504A1 (en) | 2021-08-17 | 2023-02-23 | 한국과학기술원 | Antisense oligonucleotide targeting cav3.1 gene and uses thereof |
WO2023021184A1 (en) | 2021-08-19 | 2023-02-23 | Neumirna Therapeutics Aps | Antisense oligonucleotides targeting adenosine kinase |
WO2023152369A1 (en) | 2022-02-14 | 2023-08-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Nucleic acid mir-9 inhibitor for the treatment of cystic fibrosis |
WO2024017990A1 (en) | 2022-07-21 | 2024-01-25 | Institut National de la Santé et de la Recherche Médicale | Methods and compositions for treating chronic pain disorders |
EP4332239A1 (en) | 2022-08-30 | 2024-03-06 | Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. | Mir-based assay for gastro-entero-pancreatic neuroendocrine tumor diagnosis and prognosis |
WO2024047022A1 (en) | 2022-08-30 | 2024-03-07 | Istituto Romagnolo Per Lo Studio Dei Tumori "Dino Amadori" - Irst S.R.L. | Mir-based assay for gastro-entero-pancreatic neuroendocrine tumor diagnosis and prognosis |
Also Published As
Publication number | Publication date |
---|---|
CA2385853A1 (en) | 2001-04-12 |
EP1224280A2 (en) | 2002-07-24 |
IL148916A0 (en) | 2002-09-12 |
JP2003511016A (en) | 2003-03-25 |
AU7406700A (en) | 2001-05-10 |
WO2001025248A3 (en) | 2001-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1224280A2 (en) | Design of high affinity rnase h recruiting oligonucleotide | |
Gryaznov | Oligonucleotide N3′→ P5′ phosphoramidates as potential therapeutic agents | |
US9951333B2 (en) | Antisense design | |
CN106795200B (en) | Galnac phosphoramidites, nucleic acid conjugates thereof, and uses thereof | |
US5532130A (en) | Methods and compositions for sequence-specific hybridization of RNA by 2'-5' oligonucleotides | |
JP3558230B2 (en) | Stabilized oligonucleotides and their use | |
JP2005522997A (en) | Oligonucleotides containing alternating segments and uses thereof | |
JP2008501694A5 (en) | ||
JP2005500025A5 (en) | ||
EP2458005A1 (en) | Fgf21 cis-element binding substance | |
JP2014527401A5 (en) | ||
JP2008501693A5 (en) | ||
WO2008151631A2 (en) | Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis | |
RU2002105021A (en) | OLIGONUCLEOTIDES FOR INHIBITING HUMAN eg5 EXPRESSION | |
CN105121452A (en) | Tricyclic nucleosides and oligomeric compounds prepared therefrom | |
JP2021520387A (en) | Use of FUBP1 inhibitors to treat hepatitis B virus infection | |
Liczner et al. | Beyond ribose and phosphate: selected nucleic acid modifications for structure–function investigations and therapeutic applications | |
CA2419563C (en) | Chimeric antisense of arabinofuranose analogue and deoxyribose nucleotides | |
AU2001289448A1 (en) | Chimeric antisense oligonucleotides of arabinofuranose analogues and deoxyribose nucleotides | |
Rusling et al. | Combining nucleoside analogues to achieve recognition of oligopurine tracts by triplex-forming oligonucleotides at physiological pH | |
WO2003025173A1 (en) | Novel antisense oligonucleotide derivatives to hepatitis c virus | |
Verheijen et al. | Incorporation of a 4-hydroxy-N-acetylprolinol nucleotide analogue improves the 3′-exonuclease stability of 2′-5′-oligoadenylate-antisense conjugates | |
Berk | Alternative scaffolds for systemic delivery of small interfering RNAs | |
Engels et al. | Chemistry of oligonucleotides | |
Opalinska et al. | Rationally Targeted, Conformationally Constrained, Oxetane‐Modified Oligonucleotides Demonstrate Efficient Gene‐Silencing Activity in a Cellular System |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 148916 Country of ref document: IL Ref document number: 74067/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2385853 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2001 528192 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000962273 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000962273 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000962273 Country of ref document: EP |